Prefilled Syringes or Peptide Pills? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Prefilled Syringes or Peptide Pills?
The impact of new delivery technologies in designing peptide therapies.


Pharmaceutical Technology
Volume 37, Issue 5, pp. 46-49

References

1. R. Lax, PharManufacturing website, "The Future of Peptide Development in the Pharmaceutical Industry," http://www.polypeptide.com/, accessed Apr. 4, 2013.

2. J. Reichert, Peptide Therapeutics Foundation website, "2010 Development Trends for Peptide Therapeutics," http://www.peptidetherapeutics.org/, accessed Apr. 4, 2013.

3. P. Vlieghe et al., Drug Discov. Today 15 (1-2) 40-56 (2010).

4. C.A. Lipinski et al., Adv. Drug Deliv. Rev. 46 (1-3) 3-26 (2001).

5. A. Ruggiero et al., Proc. Natl. Acad. Sci. USA 107 (27): 12369-12374 (2010).

6. J.L. Cleland et al., Curr. Opin. Biotechnol. 12 (2) 212-219 (2001).

7. Q. Ye et al., J Control. Rel. 64 (1-3) 155-166 (2000).

8. F. Tiberg and F. Johhnson, On Drug Delivery website, "Lipid-Liquid Crystals for Parenteral Sustained-Release Applications," http://www.ondrugdelivery.com/, accessed Apr. 4, 2013.

9. C. Valery et al., Proc. Natl. Acad. Sci. USA 100 (18) 10258-10262 (2003).

10. J. Heller, Adv. Drug Deliv. Rev. 10 (1-3) 163-204 (1993).

11. A. Lalatsa, "Peptide and Protein Therapeutics: Impact of New Delivery Technologies and Clinical Development" in Fundamentals of Pharmaceutical Nanosciences, I.F. Uchegbu, A.G. Schatzlein, W.P. Cheng and A. Lalatsa, Eds. (Springer, New York, 2013).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here